A randomized, open label, phase II study comparing efficacy of pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant Non-Small Cell Lung Cancer patients who have failed first-line EGFR TKI

Trial Profile

A randomized, open label, phase II study comparing efficacy of pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant Non-Small Cell Lung Cancer patients who have failed first-line EGFR TKI

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2016 New trial record
    • 07 Jun 2016 Primary endpoint has not been met. (PFS), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top